Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. and Niowave, Inc. announced a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, combining Aptevo's proprietary molecules and multispecific antibody platforms with Niowave's radioisotopes and supply capabilities. Concurrently, Niowave made an initial equity investment of approximately $500,000 in Aptevo, acquiring 98,522 common shares and warrants for 53,201 shares, representing an initial 7.9% ownership. Niowave has the potential to increase its stake to up to 19.99% through additional purchases and warrant exercises. This partnership marks Aptevo's expansion into the radiopharmaceutical therapeutic development space.

Aptevo Therapeutics Inc. reported a net loss of $(6.7) million for the first quarter of 2026, an increase from $(6.4) million in the prior year. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows from operations. Cash and cash equivalents decreased to $14.5 million as of March 31, 2026, despite raising $0.9 million through common stock issuance in the quarter and an additional $0.2 million subsequently.

Aptevo Therapeutics provided a Q1 2026 business update, highlighting strong clinical data for its lead candidate, Mipletamig, in frontline acute myeloid leukemia (AML). The company reported an 87% clinical benefit rate and 81% remission (CR or CRi) with no cytokine release syndrome. Aptevo also secured a $60 million equity line of credit, enhancing financial flexibility through 2029, and completed an executive leadership transition with Jeff Lamothe appointed CEO.

Aptevo Therapeutics reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial, demonstrating an 87% clinical benefit rate and an 81% remission rate across 31 evaluable patients. These results significantly outperform historical benchmarks, showing strong clinical activity and a favorable safety profile. The company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose in 2026, with the program now entering its final stage of dose optimization.